Abstract | BACKGROUND: METHODS: In this open-label, single-center phase I study, cardiovascular vital signs were recorded following tyramine challenges during placebo and STS 6 mg/24 hr treatment. Subjects were observed for clinical signs and symptoms of a pressor response and/or potential hypertensive crisis during and following the challenges. RESULTS: Ingestion of tyramine-enriched meals following 13 consecutive days of treatment with the STS 6 mg/24 hr (pharmacokinetic steady-state) produced no clinically significant changes in cardiovascular vital signs in 12 healthy adult male subjects. No evidence of a tyramine pressor effect on systolic blood pressure or evidence of hypertensive crisis occurred during the STS treatment. CONCLUSION: These results suggest that STS 6 mg/24 hr may be administered without concern for dietary tyramine consumption.
|
Authors | Lawrence F Blob, Melvin Sharoky, Bryan J Campbell, Eva M Kemper, Michelle Gilmor Gilmor, Chad M VanDenberg, Albert J Azzaro |
Journal | CNS spectrums
(CNS Spectr)
Vol. 12
Issue 1
Pg. 25-34
(Jan 2007)
ISSN: 1092-8529 [Print] United States |
PMID | 17192761
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Monoamine Oxidase Inhibitors
- Selegiline
- Tyramine
|
Topics |
- Administration, Cutaneous
- Adolescent
- Adult
- Blood Pressure
(drug effects)
- Cheese
- Double-Blind Method
- Drug Interactions
- Drug-Related Side Effects and Adverse Reactions
- Humans
- Male
- Middle Aged
- Monoamine Oxidase Inhibitors
(administration & dosage, pharmacology)
- Selegiline
(administration & dosage, pharmacology)
- Tyramine
(pharmacology)
|